TruthArchive.ai - Related Video Feed

Dr. Hotez explains that while vaccines are often described as miraculous, the development was not a four-month process but a seventeen-year effort dating back to the post-SARS period. After SARS emerged in 2003, researchers identified the spike protein as the virus’s soft underbelly and began experimental vaccine development. When the COVID-19 sequence was released in January, the coronavirus community quickly concluded that a vaccine could be made, and attention turned to which technology would be fastest and most enduring. All vaccines discussed (AstraZeneca, Pfizer, Moderna, J&J, and the one being scaled in India) target the spike protein. He emphasizes that this was a deliberate long-term program, not a rushed push. Nicole notes the broader context of vaccine safety, particularly on a day when a vaccine-skeptical witness testified before the Senate Homeland Security Committee. Dr. Hotez clarifies that the virus behind the current pandemic comes from a family of coronaviruses scientists have studied for a long time, and that once specifics emerged, researchers could finalize the vaccine approach. He reiterates the importance of reassurance about safety in light of public skepticism. Dr. Hotez highlights the role of the NIH and the National Institute of Allergy and Infectious Diseases, led by Tony Fauci, and Francis Collins at NIH, in launching a major coronavirus program beginning in 2003. This funding enabled the development of some of the first prototype vaccines, illustrating a deliberate US government and NIH investment to advance vaccine research. He notes the ongoing need to assess rollout and production robustness, as this technology is brand new, and additional vaccines will be necessary to vaccinate populations. Looking ahead, the conversation acknowledges that the United States will require four or five different vaccines to achieve broad vaccination coverage, rather than relying solely on the two mRNA vaccines. The UK has begun vaccinations, marking an initial step, with plans to scale in the United States in the coming days. The discussion underscores a long road ahead to ensure scalable production, distribution, and multiple vaccine options to meet demand.

Dr. Kizzmekia Corbett and her team have been studying spike proteins in viruses for the past 10 years. They discovered that controlling the spike protein's shape is crucial for creating effective vaccines. Using their knowledge from previous research on MERS coronavirus, they quickly applied their techniques to develop a vaccine for the current virus in collaboration with Moderna. By January 10th last year, they obtained the virus sequences and produced the vaccine over the weekend. They tested the vaccine on mice and found that it generated antibodies. Dr. Corbett mentions that they are now working on addressing the variants of the virus.

On October 6, 2021, I met with my manager, Conwell Gill, a principal scientist at Pfizer. We discussed the ethics of giving people experimental booster shots for money. mRNA vaccines have been around for 50 years but never made it to clinical use due to side effects. Pfizer and Moderna used the emergency of the pandemic to push through their vaccines. Pfizer collaborated with Beyond Tech on mRNA technology for COVID-19. Everything was new and rushed due to the pandemic. There was no time to think, only to act.

In 1965, coronavirus was identified as a pathogen that could be modified for various purposes. The first transatlantic coronavirus experiment took place in 1966, followed by human trials in 1967. In the 1970s, coronavirus was manipulated in animals, and by 1990, it was recognized as a problem for dogs and pigs. Pfizer filed the first spike protein vaccine patent in 1990. It was known since then that coronavirus mutates too quickly for vaccines to be effective. In 2002, the University of North Carolina Chapel Hill patented an infectious replication defective clone of coronavirus, funded by Anthony Fauci. SARS 1.0 was engineered and not a naturally occurring phenomenon.

Coronavirus was isolated in 1965 and quickly identified as a pathogen for experimentation. In 1966, the first COV model was used in human manipulation experiments. By 1990, Pfizer patented a spike protein vaccine for coronavirus. Research showed vaccines were ineffective due to the virus mutating rapidly. In 2002, the University of North Carolina patented an infectious replication defective clone of coronavirus, funded by Anthony Fauci. This work preceded SARS 1.0 by a year, suggesting engineered origins.

Coronavirus was isolated in 1965 as one of the first infectious replicatable viral models, associated with the common cold. In 1966, the very first COV coronavirus model was used as a transatlantic biological experiment in human manipulation. In 1967, the first human trials on inoculating people with modified coronavirus were conducted. Between 1975 and 1977, we started modifying coronavirus by putting it into different animals, pigs and dogs. By 1990, Pfizer's first spike protein vaccine patent for coronavirus was filed. From 1990 to 02/2018, every publication on coronavirus vaccines concluded that coronavirus escapes the vaccine impulse because it mutates too quickly. In 02/2002, UNC Chapel Hill patented ‘an infectious replication defective clone of coronavirus’ funded by NIAID's Anthony Fauci from 1999 to 02/2002. That work allegedly preceded SARS-1; SARS is the research developed by humans weaponizing a life system model to attack human beings, patented in 02/2002.

Last year, we had to slow down our phase 3 study to ensure diversity in participants. We were thrilled to achieve 47% diversity in the end. The news of our vaccine's 95% efficacy was a memorable moment, with Tony Fauci expressing disbelief. Our team's hard work led to delivering 100 million doses by March, on our way to reaching 800-1 billion doses this year.

In a meeting on October 6, 2021, questions arose about the ethics of administering experimental booster shots and whether financial motives influenced their rollout. The discussion highlighted that while mRNA vaccines have been researched for decades, they had not previously reached clinical trials due to known side effects. Pfizer and Moderna utilized the pandemic's emergency status to expedite their vaccines. A collaboration with BioNTech, initiated before COVID-19, led to the development of mRNA technology. The urgency of the pandemic required rapid action, leaving little time for thorough deliberation. Katherine Janssen, a key figure in vaccine development at Pfizer, emphasized the ongoing efforts to create effective vaccines against COVID-19.

Trump gave Moderna's COO a billion-dollar check to develop a vaccine quickly, bypassing FDA regulations. Human trials began after testing on mice. Many doubted the speed and safety of the process, but the vaccine was developed in 6 months. Concerns were raised by vaccine experts about the rushed development.

In Davos, in January 2020, we had a conversation about a vaccine for COVID-19. At that time, COVID-19 wasn't a major concern, and we were focused on developing the vaccine.

We are generating real-time data on mRNA vaccines, which have been in development for years due to side effects. Pfizer and Moderna used the pandemic to accelerate their development. The collaboration with BioNTech on flu led to the quick rollout of the mRNA vaccine. Clinical trials skipped phases, causing uncertainty. Concerns arise about vaccine distribution and the need for booster shots. Politics play a role in decision-making.

I've been involved in over 50 vaccines, including mRNA vaccines. mRNA is like DNA, giving cells instructions to make proteins. This technology was originally for gene therapy, now used for vaccines. It's a new, experimental technology never used in humans before COVID. Animal studies were skipped for COVID vaccines, a novel approach.

We discussed pandemic readiness with Tony, proposing a mock outbreak to test fast vaccine production. Despite skepticism, we aimed to deliver a GMP dose within 60 days. When news of a new coronavirus emerged, we quickly recognized the need for action. Transitioning from traditional egg-based vaccine production to new methods requires disruptive innovation. The urgency for a faster, disruptive approach to address outbreaks is evident. The potential for rapid response to novel viruses by sharing RNA sequences globally is crucial. Investigation into motives for outbreaks is essential.

On January 10th, the speaker received the genetic sequence of the virus from Chinese authorities. They immediately designed and manufactured a vaccine, using a computer algorithm to generate the vaccine design in just a few hours. The code for the vaccine was downloaded from a Chinese website, and the speaker expresses gratitude to the Chinese authorities for sharing it. However, there are concerns about the Chinese government not sharing data and not isolating the virus. The speaker questions the reliability of positive results from live animal samples. Overall, the situation is not what was initially expected.

Developing a vaccine is crucial to controlling the pandemic. Normally, it takes about five years to create a new vaccine, including testing for safety and effectiveness. However, efforts are being made to compress this timeline to around 18 months. The RNA platform shows promise in speeding up production. Ensuring a vaccine's effectiveness and safety, especially for older individuals, is challenging. We must avoid compromising safety while increasing efficacy. Decision-making regarding the use of a new vaccine will be based on limited data to expedite progress. Supporting the development of the most promising candidates, building production facilities, and conducting safety testing require a global collaborative effort. Our foundation is heavily involved in funding vaccines, including for developing countries. It's encouraging to see various medications emerging, such as Moderna, CureVac, Stamovi, and Logovac, which require investment.

In 2012, DARPA started the ADEPT Protect p3 program, aiming to use gene-encoded vaccines based on RNA or DNA to prevent pandemics within 60 days. This approach was already in progress when President Trump launched Operation Warp Speed in response to COVID-19. The military had been working on mRNA vaccines since 2012, with Moderna receiving its first contract in 2013. The military has various biological threat programs, including those for Smallpox, Monkeypox, and anthrax. The idea of mRNA vaccines originated from the military, not Pfizer or Moderna, and it was not a direct response to the Wuhan outbreak. Emergency use authorization, primarily for the military, was later applied to the public during the COVID-19 pandemic.

We discussed pandemic readiness and the speed of mRNA technology. I proposed a simulation to create a vaccine within 60 days, which was initially met with skepticism. However, due to our work on personalized cancer vaccines, we were prepared. When news of a new coronavirus emerged, we quickly got the sequence and began working on a vaccine. The conversation shifted to the need for disruptive entities to accelerate vaccine development, moving away from traditional methods like egg-based production. The urgency for innovative solutions to address outbreaks was emphasized.

In 2015, a 153-page agreement between Moderna and the US government reveals collaboration with Dr. Barrick on mRNA tech for a coronavirus vaccine. The NIH co-owns the vaccine candidates with Moderna. This predates current events and raises questions about government involvement in vaccine ownership.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus (attenuated), a killed virus, or just a piece of the virus, like the spike. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which is how the pandemic will end.

Big companies said it wasn't possible, but Trump gave Moderna's COO $1 billion to develop a vaccine quickly. They started human trials after testing on mice. Many were skeptical, but the vaccine was ready in 6 months. Some experts raised concerns about the rushed development process.

A year ago, the speaker requested data from Emma, including clinical trials from medical companies before they sought marketing authorization for their products. Regarding Pfizer, the speaker notes that the company submitted a clinical trial that started on January 14, 2020. The speaker questioned a Pfizer representative about how Pfizer started testing a vaccine in January 2020, just days after the Chinese government released DNA data about the virus in December 2019, but the representative declined to answer. The speaker also mentions that Moderna submitted trials dating back to 2017. The speaker asked the CEO of Moderna how it was possible to submit vaccine tests years before the virus was discovered in December 2019. The speaker states that these are legitimate questions that people are asking, but unfortunately, the companies are declining to answer.

In late 2019, I first heard about a new virus in China. Initially, I thought it would be like SARS or MERS, but after attending Davos 2020, I realized it could be a pandemic. We are partnering with CP to develop a vaccine quickly, with the US government's help. SEPI is funding the project, and we aim to produce clinical-grade material for testing. This endeavor is unprecedented, and we are working together to achieve it. When the pandemic hit, we shifted focus to producing a billion doses. It's a challenging but necessary task.

Moderna and BioNTech used the first sequence of the SARS CoV-2 genome, published on January 10th, to develop their vaccines. Moderna relied solely on the published data and never had the live virus on their site. This highlights the significance of digitizing biology, as Moderna, a leading company in biology, faced a software problem rather than a biological one.

We discussed pandemic readiness with Tony, proposing a rapid response simulation. Despite skepticism, we aimed to produce a GMP dose within 60 days. In December, upon learning of the new coronavirus, we swiftly obtained its sequence. Transitioning from egg-based vaccine production to a more efficient method requires extensive testing and could take a decade. An innovative, disruptive approach may be necessary to address future outbreaks effectively. The potential for a quick response to novel viruses, like avian strains in China, highlights the need for agile solutions.

In 2015, a 153-page confidential agreement between Moderna and the US government reveals collaboration with Dr. Barrick on mRNA coronavirus vaccines. The NIH co-owns the vaccine candidates with Moderna. This predates current events and raises questions about ulterior motives.